2013 AAPB Annual Meeting


Keynote Speaker

KEY1: Keynote Address: Training Super Human Brain Heroes

Thursday, March 14, 2013
5:15 PM to 6:30 PM

Training Super Human Brain Heroes

Athletic performance has in the past focused on training the body only. However, an athlete who can exercise volitional control of the levels of cognitive engagement and arousal of brain and body has an advantage during practice and competition. These concepts have received resistance and under utilization because research has been observation of specific skills alone. The reinvention of brain-wave technologies that are practical to implement has allowed us to build upon the previous years of research and theory. This presentation will introduce and provide the foundation for a brain performance evaluation and training model. The talk will address the practical barriers that have been overcome through significant technology developments and outcomes from individual athletes and group studies.

About Dr. Sherlin:
Leslie Sherlin, PhD is a co-founder of Nova Tech EEG, Inc., and has been practicing qEEG analysis and neurofeedback in client care since 2002. In 2008 Dr. Sherlin focused his efforts in the domain of athlete performance when he became employed as the Chief Science Officer for Neurotopia, Inc. where he leads the science and application efforts of athlete brain training. In early 2013 he will complete his professional re-specialization in sport psychology and a postdoctoral fellowship with Pinnacle Performance at D.I.S.C. Sport and Spine Center in Marina Del Rey, CA. Dr. Sherlin holds several academic positions and has served as the President for the International Society for Neurofeedback and Research and is currently serving as Chair-Elect for the BCIA Board. He is certified at the Diplomat level in quantitative electroencephalography and is BCIA Board Certified both in Biofeedback and Neurofeedback.

 

KEY2: Keynote Address: Neural Devices and Biofeedback for Rehabilitation...

Friday, March 15, 2013
9:30 AM to 10:30 AM

Neural Devices and Biofeedback for Rehabilitation of the Damaged Central Nervous System

Brain-machine interfaces (BMI) and biofeedback technology have the potential to dramatically improve quality of life after paralysis resulting from spinal cord injury, stroke or traumatic brain injury. We demonstrated that brain activity can be used to control Functional Electrical Stimulation (FES) delivered to muscles and reanimate simple movements of an otherwise paralyzed wrist. In addition to direct muscle stimulation, another promising approach is intraspinal stimulation. We quantified the hand and arm movements evoked by cervical spinal stimulation. In addition to directly restoring movements, intraspinal stimulation may also aid in guiding recovery and promoting regeneration after injury to the spinal cord. Biofeedback via neural interfaces may also improve quality of life after brain injury. We have evidence that feedback of muscle activity, routed through a computer game, can improve hand function following stroke, traumatic brain injury, or for children with cerebral palsy.

About Dr. Moritz:
Chet Moritz received his PhD from the University of California, Berkeley, studying the biomechanics of human movement. He then completed a post-doc at the University of Colorado investigating the neural control of precision hand movement. A second post-doc at the University of Washington began his interest in brain-computer interfaces and neuroprosthetic technology to treat paralysis. His is now an Assistant Professor in the departments of Rehabilitation Medicine and Physiology & Biophysics. His research uses a combination of animal models and human studies to explore novel treatments for paralysis and paresis following injury to the central nervous system (e.g., SCI, TBI, Stroke, and cerebral palsy).

 

KEY3: Keynote Address: Chronic Stress, Cell Aging, and Psychobiological Resilien

Friday, March 15, 2013
4:45 PM to 5:45 PM

Chronic Stress, Cell Aging, and Psychobiological Resilience

Under times of chronic psychological stress people are said to have Aged before your eyes. Emerging scientific research is illuminating how stress is transduced into biochemical signaling cascades that can accelerate immune system aging and accumulation of oxidative damage. On the psychological side, research increasingly highlights the role that maintaining positive affect under stress, staying mindful and present-focused, and decreasing threat sensitivity appear to play in facilitating psychobiological resilience. Exciting and novel applications of complexity theory are helping understand how stress and aging drive key bodily systems out of balance. As we age, there is not only a loss of flexibility within biological systems that respond to and help us cope with stress, but there is also an erosion of the dynamic communication between systems. The presentation will provide an overview of these psychological and biological mechanisms, highlighting cutting-edge developments in the field and their potential translational applications.

About Dr. Aschbacher:
Dr. Aschbacher investigates how chronic stress exposure and emotion-regulation during stress affect the autonomic nervous system, immune system, and the bodys endogenous healing mechanisms. Her particular interest has been in identifying novel potential intervention targets to increase psychobiological resilience. Dr. Aschbacher conceptualizes the psychological and biological aspects of her work, not merely as separate phenomena to be correlated, but as an integrated, bidirectional and dynamic brain-body system. For example, she finds that psychological states associated with greater positive affect tend to be associated with an altered pattern of dynamic interactions between the sympathetic and parasympathetic nervous systems during stress, which is associated with lower levels of markers of inflammation, oxidative stress and metabolic risk.

KEY4: Keynote Address: Self-Management in Chronic Pain: When Pills & Procedures

Saturday, March 16, 2013
1:45 PM to 2:45 PM

Self-Management in Chronic Pain: When Pills & Procedures Are Inadequate

Despite advances in understanding the neurophysiology of pain, conventional medical and pharmacological treatments for patients with participant pain are only modestly effective in alleviating symptoms and improving physical and emotional functioning. Provider reliance on narrow, unidimensional views of patients has guided assessment and treatment. The rationale for the integrated, biopsychosocial approach to patients with chronic pain will be provided and a description of a more comprehensive assessment and integrated treatment based on this approach will be outlined. In addition, information will be provided regarding the application of biopsychosocial principles in a patient-focused approach that emphasizes self-management. The lecture will provide practical information that clinicians and clinical investigators can use in research, assessment, and treatment of the range of patients with diverse pain chronic pain syndromes. Some prognostications about the future of pain management will be offered..

About Dr. Turk:
Dennis C. Turk, PhD, is John and Emma Bonica Professor of Anesthesiology & Pain Research and Director of the Center for Research in Pain Impact, Measurement, & Effectiveness (C-PRIME) at the University of Washington. He has over 500 publications in scientific journals and scholarly texts, and has written and edited 20 volumes. He is currently Editor-in-Chief of The Clinical Journal of Pain and Pain Management Today. He is co-coordinator of the Initiative on the Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT), a fellow of the American Psychological Association, Society of Behavioral Medicine, and Academy of Behavioral Medicine Research, and recipient of the American Psychological Association Outstanding Scientific Contribution Award (1993) among many other awards. An international survey conducted by the University of Regina (Canada), published in The Pain Clinic (2001), and identified Dr. Turk as one of the top 10 leaders in pain research and treatment development.

 
Back To Top